Status:
COMPLETED
The Safety and Efficacy of Nexalin Trans-cranial Electrical Stimulation Stimulation for the Treatment of Depression
Lead Sponsor:
University of Pennsylvania
Collaborating Sponsors:
Carrier Clinic
Conditions:
Depression
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The purpose of this research study is to determine whether Nexalin Trans-Cranial Electrical Stimulation (TES) is an effective treatment for depression among patients who are candidates for ECT. A seco...
Detailed Description
A 2x2 factor Randomized Controlled Trial with block randomization. Inpatient subjects at the Carrier Clinic who are referred for ECT will be recruited, typed regarding their acceptance of ECT, and ran...
Eligibility Criteria
Inclusion
- In-patients at the Carrier Clinic
- Adults over age 18 and under age 65
- Able to speak, read and write fluently in English, assessed by the study coordinator at Carrier Clinic
- Screened Negative for alcohol abuse and/or dependence
- Able to provide informed consent, assessed by the study coordinator at Carrier Clinic
- Referred for ECT
- Not currently taking hypnotics or be prescribed hypnotics during the Nexalin trial
- Not pregnant or intending to become pregnant during the study
- Committed to completion of the study
Exclusion
- Medically or psychiatrically unstable, where the severity of the illness prohibits the subject from engaging in study procedures.
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 17 2018
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT03277846
Start Date
September 1 2017
End Date
May 17 2018
Last Update
October 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Carrier Clinic
Belle Mead, New Jersey, United States, 08502